Business
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatm
About this update from Capricor Therapeutics, Inc.
[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YaI1GjtfVRH2kLVsjMQa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"text","content":"– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET –","length":68,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD).","length":472,"tagName":"p"},{"type":"text","content":"The webinar will provide patients and families with an overview of the HOPE-3 results and how the findings inform ongoing regulatory discussions, including next steps with the U.S. Food and Drug Administration (FDA). The webinar will be held on Wednesday, December 17, 2025, at 1:00 p.m. ET. Participants are encouraged to submit questions in advance.","length":351,"tagName":"p"},{"type":"text","content":"To register for the webinar, please click here.","length":47,"tagName":"p"},{"type":"text","content":"For additional details, please visit Parent Project Muscular Dystrophy’s website. A replay of the webinar will be made available on PPMD’s website.","length":147,"tagName":"p"},{"type":"text","content":"About Capricor Therapeutics","length":27,"tagName":"p"},{"type":"text","content":"Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for the treatment of Duc...